We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Promising drug discovery for the effects of Alzheimer’s disease
News

Promising drug discovery for the effects of Alzheimer’s disease

Promising drug discovery for the effects of Alzheimer’s disease
News

Promising drug discovery for the effects of Alzheimer’s disease

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Promising drug discovery for the effects of Alzheimer’s disease"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Scientists from the University of South Australia, along with colleagues from Third Military Medical University in Chongqing, China, have discovered the drug Edaravone can alleviate the progressive cognitive deficits of Alzheimer's disease, a major social and economic burden worldwide.


The discovery has been published in the journal Proceedings of the National Academy of Sciences.


Edaravone is currently available only in some Asian countries for the treatment of ischemic stroke -- the most common type of stroke which is caused by blood clots.


Lead researcher Professor Xin-Fu Zhou, who is UniSA's Research Chair in Neurosciences, says Edaravone can alleviate Alzheimer's disease pathologies and improve functions of learning and memory -- in a mouse model of the disease -- by multiple mechanisms.


"Edaravone can bind the toxic amyloid peptide which is a major factor leading to degeneration of nerve cells," Prof Zhou says.


Prof Zhou says lessons from failures of current clinical trials suggest that targeting multiple key pathways of the Alzheimer's disease pathogenesis is necessary to halt the disease progression.


"Edaravone can suppress the toxic functions of amyloid beta to nerve cells -- it is a free radical scavenger which suppresses oxidative stress that is a main cause of brain degeneration," he says.


"The drug can suppress the production of amyloid beta by inhibiting the amyloid beta production enzyme. It also inhibits the Tau hyperphosphorylation which can generate tangles accumulated in the brain cells and disrupt brain functions."


The research is a collaboration between Prof Zhou's lab within UniSA's Sansom Institute for Health Research and School of Pharmacy and Medical Sciences, and labs led by Prof Yanjiang Wang in Chongqing, China.


The researchers stress Edaravone should not be used for Alzheimer's patients before appropriate clinical trials are undertaken. Prof Zhou is seeking investment and partnership opportunities to further the research.


Note: Material may have been edited for length and content. For further information, please contact the cited source.

University of South Australia   press release


Publication

Shu-Sheng Jiao, Xiu-Qing Yao, Yu-Hui Liu, Qing-Hua Wang, Fan Zeng, Jian-Jun Lu, Jia Liu, Chi Zhu, Lin-Lin Shen, Cheng-Hui Liu, Ye-Ran Wang, Gui-Hua Zeng, Ankit Parikh, Jia Chen, Chun-Rong Liang, Yang Xiang, Xian-Le Bu, Juan Deng, Jing Li, Juan Xu, Yue-Qin Zeng, Xiang Xu, Hai-Wei Xu, Jin-Hua Zhong, Hua-Dong Zhou, Xin-Fu Zhou, Yan-Jiang Wang. Edaravone alleviates Alzheimer’s disease-type pathologies and cognitive deficits.   Proceedings of the National Academy of Sciences, Published Online April 6 2015. doi: 10.1073/pnas.1422998112


Advertisement